Pharmaceutical/Biotech - Health Security & Infectious Diseases
Strategic Profile
SIGA maintains a strong strategic position through four key pillars: continued partnership with the U.S. government (primary revenue source), advancing regulatory approvals for new TPOXX indications and formulations, expanding international market access, and developing complementary therapeutic areas. The company has strong financial flexibility with $182 million in cash, no debt, and is pursuing post-exposure prophylaxis (PEP) and pediatric formulations to drive future growth.
Cyborg Score Rationale
SIGA demonstrates solid fundamentals with a proven, approved product generating substantial government contracts, strong cash position, and clear pipeline progression. However, heavy reliance on U.S. government contracts (concentration risk) and nascent international commercial traction present challenges that prevent a higher rating.
Top Insights
U.S. government contracts are primary revenue driver with $79 million in Q2 2025 product deliveries and $27 million in development funding, demonstrating strong biosecurity demand
FDA submission targeted for first half of 2026 for TPOXX PEP (post-exposure prophylaxis) indication represents clear catalyst for new revenue stream expansion
Pediatric formulation program in partnership with BARDA addresses critical unmet need; IND submission planned for H2 2025 with clinical trials to follow shortly
Valuation discount of 93.5% below analyst fair value estimates suggests potential underpricing relative to fundamentals and pipeline potential
Named Competitors
Monoclonal antibody therapies — Emerging alternatives for orthopoxvirus treatment